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Background: Diabetes mellitus is (DM) a global public health problem and a complex disease 
characterized by chronic hyperglycemia that leads to long-term macrovascular and microvascular 
complications. Recent studies have reported the role of hematological indices in contributing to 
the vascular injury in diabetic patients. Thus, the aim of this study was to determine hematological 
indices and their correlation with fasting blood glucose level and anthropometric measurement 
in type 2 DM patients in comparison with healthy controls.
Methods: A comparative cross-sectional study was conducted at the chronic illness clinic of 
Gondar University Hospital from February to April 2015. A total of 296 participants (148 cases 
and 148 healthy controls) were selected using systematic random sampling technique. Data were 
collected using a pretested structured questionnaire. Fasting blood glucose levels and hema-
tological indices were determined by using Bio Systems A25 and Sysmex-KX 21N analyzers, 
respectively. Independent sample t-test, Mann–Whitney U-test, and correlation statistics were 
used. A P-value ,0.05 was considered as statistically significant.
Result: There was significant difference in red blood cell distribution width (47.3±2.6 fL vs 
45.2±3 fL) between diabetic patients and controls. Total white blood cells in 103/µL (6.59±1.42 
vs 5.56±1.38), absolute lymphocyte count in 103/µL (2.60±0.70 vs 2.04±0.63), and absolute 
neutrophil count in 103/µL (3.57±1.46 vs 3.11±1.04) increased significantly in diabetic patients 
compared with controls, respectively. Among platelet indices, mean platelet volume (10.4±1.1 fL 
vs 9.9±1.1 fL) and platelet distribution width (14.5±2.1 fL vs 13.4 ±2.1 fL) were found to be 
significantly increased in the diabetic patients (P,0.05). Anthropometric measurements sig-
nificantly correlated with white blood cell and platelet indices.
Conclusion: The study showed statistically significant difference in some hematological para-
meters of diabetic patients compared to controls. Thus, hematological indices could be useful 
indicators of vascular complication and glycemic control in type 2 DM patients.
Keywords: Ethiopia, fasting blood glucose, Gondar, hematological indices, type 2 diabetes 
mellitus
Introduction
Diabetes mellitus (DM) encompasses a heterogeneous group of disorders characterized 
by hyperglycemia associated with multiple disorders including metabolic, cellular, and 
blood disturbances leading to vascular complications.1
The number of people suffering from type 2 (T2) DM has been increasing due to the 
aging population, urbanization, and low physical activity. According to the International 
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Diabetes Federation (IDF) estimate of 2013, 382 million 
(8.3%) adults had diabetes worldwide. The number has been 
increasing by twofold over the past 20 years, and 80% of the 
people with diabetes particularly live in low- and middle-
income countries.2 Ethiopia experiences a heavy burden of 
communicable infectious diseases and nutritional deficiencies. 
Currently, it is also being faced by the rising magnitude of 
noncommunicable diseases like DM. In Ethiopia, although a 
nationwide surveillance on occurrence of DM has not been 
documented, the 2012 IDF report indicated an estimated DM 
prevalence of 3.32%.3
The overall temporal burden of hyperglycemia is respon-
sible for DM complications and adverse outcomes.4 Patients 
with T2DM have increased risk of cardiovascular disease 
(CVD) related with atherogenic dyslipidemia, coronary artery 
disease, and myocardial infarction. Myocardial infarction is 
the leading cause of morbidity and mortality worldwide.5 The 
increased vascular risk associated with T2DM is likely to be 
multifaceted, but lipid abnormalities play an important role. 
It is important to note that dyslipidemia is more atherogenic 
in diabetic than in nondiabetic patients.6 T2DM is a part of 
metabolic syndrome that comprises dyslipidemia, hyperten-
sion, and impaired hematological indices.7
Several hematological changes affecting the red blood 
cells (RBCs), white blood cells (WBCs), and the coagulation 
factors are shown to be directly associated with DM.8 Other 
hematological abnormalities reported in the DM patients 
include RBCs, WBCs, and platelet dysfunction.9,10
Systematic review and meta-analysis of cross-sectional 
and prospective studies have shown that the number of periph-
eral WBCs such as basophils, eosinophils, and neutrophils 
increased, with no change in the number of monocytes in 
patients with T2DM.10
Hyperglycemia results in disturbances in cel lular meta-
bolism due increased produc tion of reactive oxygen species 
(ROS) and nonenzymatic glycation of many macromolecules, 
which lead to changes in cellular structure and function, 
and formation of advanced glycation end products (AGEs). 
The formation of AGEs enhances metabolic disturbances 
and also increases reactive oxygen species production via 
interaction with the specific receptor for AGE (RAGE).11,12 
This causes changes in structure and biophysical properties 
of the basement membrane which further causes changes in 
permeability and vasodilatation of blood vessels.13
A study suggested that high platelet activity enhances vas-
cular complica tions in DM patients.14 Mean platelet volume 
(MPV) is a marker showing platelet function and activation. 
Altered platelet morphology and function can be reflected 
as a factor for risk of microvascular and macrovascular 
diseases.15–17 Several studies have reported that increased 
platelet reactivation in patients with diabetes may confer 
less cardiovascular protection with antiplatelet therapy, par-
ticularly aspirin.18,19 It has already been demonstrated that 
insulin resistance (IR) and hyperinsulinemia are associated 
with the stimulation of erythroid progenitors and increased 
levels of inflammatory markers.20,21
Epidemiological study has indicated a close relation-
ship between the WBC count and components of metabolic 
syndrome.22 These abnormalities have been shown to mark-
edly increase blood viscosity that unfavorably affects the 
microcircula tion, leading to microangiopathy.23 Studies 
revealed that higher WBC count, as one of the major com-
ponents of inflammatory process, contributes to atheroscle-
rotic progression and CVD22,24–26 Hematological indices 
are important indicators for the evaluation of variations in 
size, number, and maturity of different blood cells. They are 
important for the assessment and management of patients with 
DM. Therefore, this study aimed at determining hematologi-
cal indices and their correlation with fasting blood glucose 
level and anthropometric measurement in T2DM patients 
in comparison with apparently healthy controls in Gondar, 
Northwest Ethiopia.
Materials and methods
Study design, period, and area
A comparative cross-sectional study was conducted from 
February to April, 2015 at the chronic illness clinic of 
Gondar University Hospital, Northwest Ethiopia. Gondar 
University Hospital has more than 500 inpatient beds and 
provides health referral service to over 5 million inhabit-
ants in Northwestern Ethiopia. As a teaching hospital, it 
plays an important role in providing teaching, research, and 
community service. The Diabetes Illness Care Follow-up 
Clinic, which was organized 2 decades ago in the Gondar 
University Hospital, has been providing service to more than 
8,000 diabetic patients.
Study participants
The study was conducted on 148 T2DM patients (59 males 
and 89 females) aged between 25 and 70 years who were fol-
lowed up at the chronic illness clinic of Gondar University 
Hospital. One hundred forty-eight (59 males and 89 females) 
age- and sex-matched apparently healthy individuals who 
had no previous history of chronic diseases were included 
as control subjects. The control group included individuals 
who were working at the University of Gondar and volunteer 
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nonremunerated blood donors at Gondar blood bank. T2DM 
patients who were severely ill, pregnant women, smokers, 
alcoholics, on antihypertensive treatment, on statins for 
abnormal lipid treatment, on insulin therapy, on anticoagulant 
therapy, and who had other chronic diseases were excluded 
from the study.
Sample size and sampling technique
Two population mean formulae were used to calculate the 
sample size using OpenEpi, version 2, open source calculator 
by considering the following assumptions: 95% confidence 
interval (two-sided), 80% power, and ratio of cases to control 
group was 1:1. Taking the mean and standard deviation (SD) 
of hemoglobin (Hgb) for T2DM and control group from a 
study conducted in Bangladesh,27 12.76 and 1.49 for T2DM 
group and 13.26 and 1.3 for control group, the sample size 
was determined to be 148 for each group. Systematic ran-
dom sampling technique was employed to select the study 
participants.
Data collection and laboratory methods
Sociodemographic data were collected by trained nurses 
at the chronic illness clinic of Gondar University Hospital 
by using semistructured questionnaire. The data regarding 
anthropometric variables such as height (to the nearest 
centimeter without shoes), weight (to the nearest 0.1 kg), 
and waist circumference (WC) (taken midway between the 
lowest rib and the iliac crest) were collected. Body mass 
index (BMI) was calculated as weight in kilograms divided 
by height in meter squared. Blood pressure (BP) was taken 
by qualified personnel using an analog sphygmomanometer 
and stethoscope. Measurements were taken from the upper 
arm with the hand at the heart level after the patient had 
been sitting for more than 5 minutes. The anthropometric 
and BP measurements were taken twice and the average 
values were used for data analysis. Five milliliters of 
fasting blood sample was collected by laboratory tech-
nologist for fasting blood glucose (FBG) determination 
after 10–12 hours of fasting with the exception of water 
and medication. FBG was estimated by following glucose 
oxidase method using Bio systems A25 (Costa Brava, 
Spain) automated clinical chemistry analyzer according 
to manufacturer’s instructions. Three milliliters venous 
blood samples were collected in test tubes, containing 
EDTA anticoagulant, for hematological tests and were 
analyzed using Sysmex KX-21N (Sysmex Corporation, 
Kobe, Japan) hematology analyzer. The results of the 
evaluation of other parameters such as Hgb, hematocrit 
(Hct), mean corpuscular volume (MCV), mean corpus-
cular hemoglobin (MCH), mean corpuscular hemoglobin 
concentration (MCHC), MPV, platelet distribution width 
(PDW), red cell distribution width (RDW), and the count 
of RBCs, WBCs, platelets, absolute lymphocytes, mixed 
cells (monocyte, basophil, and eosinophil [MID]), and 
neutrophils were recorded.
Data management and quality control
The questionnaire was pretested for its accuracy and consis-
tency prior to actual data collection and a half-day training 
program was conducted for the data collectors. Furthermore, 
the principal investigator provided feedback and corrections 
on a daily basis to the data collectors. Completion, accuracy, 
and clarity of the collected data were checked carefully on 
a regular basis. The results obtained from quality control 
samples must be within mean ± 2 standard deviation (SD) 
of the given Levy Jenning chart. Therefore, to ensure the 
quality of the final results, preanalytical, analytical, and 
postanalytical precautions were taken. Finally, the samples 
were processed within 1 hour of specimen collection in the 
hematology and clinical chemistry laboratory.
Data analysis and interpretation
Data were entered and analyzed by using Statistical Package 
for Social Sciences (SPSS) version 20 (IBM Corporation, 
Armonk, NY, USA). The data were tested for normality with 
the help of histograms, by comparison of means and medians, 
and by performing skewness and Kolmogorov–Smirnov tests. 
Data were reported as mean and SD for continuous variables, 
percentages for categorical variables, and interquartile range 
for non-normally distributed data. Variables were compared 
using an independent sample t-test for normally distributed 
data and the Mann–Whitney U-test for non-normally dis-
tributed data. The strength of association between the pairs 
of variables was assessed by Pearson’s and Spearman’s rank 
correlation coefficient. A P-value ,0.05 was considered 
statistically significant.
ethical consideration
Ethical clearance was obtained from Research and Ethical 
Review Committee of School of Biomedical and Laboratory 
Sciences, College of Medicine and Health Sciences, Univer-
sity of Gondar. A permission letter was also taken from the 
Hospital director and head of the chronic illness clinic. In 
addition, written informed consent was obtained from the 
study participants before data collection. The data were kept 
confidential by using codes rather than any personal identifier, 
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Table 1 Demographic, clinical, and anthropometric characteristics 
of the study participants at gondar University hospital, northwest 
ethiopia, 2015 (n=296)
Variables T2DM  
(Mean ± SD)
Controls 
(Mean ± SD)
P-value
age (years) 49.09±8.1 47.8±6.8 0.149
Male/female, n(%) 59 (39.9%)/89(60.15) 59 (39.9%)/89(60.15) 1.000
BMi(kg/m2) 25.4±3.2 23.2±3.1 0.000
Wc(cm) 83.02±12.6 78.67±10.2 0.001
Whr 0.88±0.88 0.84±0.66 0.000
Blood pressure (mmhg)
Systolic BP 130 (120–140)* 110 (110–120)* 0.000
Diastolic BP 80 (70–88)* 70 (70–80)* 0.000
FBg level (mg/dl) 163.7±1.33 81.3±1.08 0.000
Duration of DM 
in year
4.07±3.1 0.000
Note: *Presented as median and interquartile range.
Abbreviations: DM, diabetes mellitus; T2DM, type 2 diabetes mellitus; SD, 
standard deviation; BMi, body mass index; Whr, waist to hip ratio; FBg, fasting 
blood glucose; BP, blood pressure; Wc, waist circumference.
and the results were communicated to the physicians at the 
chronic illness follow-up clinic.
Results
Demographic, clinical, and 
anthropometric characteristics of study 
participants
A total of 296 (148 T2DM patients and 148 controls) study 
subjects were included in this study. Of the total T2DM 
patients, 59 (39.9%) were males and 89 (60.1%) were 
females. Similarly, of the total 148 healthy controls, 59 
(39.9%) and 89 (60.1%) were males and females, respec-
tively. The mean age (mean + SD) was 49.09±8.1 and 
47.8±6.7 years for T2DM patients and controls, respectively. 
The results showed that the mean levels of BMI, WHR (waist 
to hip ratio), systolic and diastolic blood pressure (BP), and 
FBG levels were significantly higher (P,0.05) in patients 
with T2DM compared to controls. The mean duration of ill-
ness since diagnosis was 4.07±3.1 years for T2DM patients. 
The mean waist circumference (WC) showed statistically 
significant difference between the two groups (P=0.001) 
(Table 1).
Comparison of hematological profile of 
the study participants
Regarding the WBC indices, statistically significant incre-
ment in total WBC (P=0.000), absolute neutrophil (P=0.012), 
and absolute lymphocyte (P=0.0001) counts were observed in 
the T2DM patients as compared to the control group. Among 
the RBC indices, only RDW showed statistically significant 
increment in T2DM (P=0.000) patients. In addition, 
statistically significant increments in MPV (P=0.001) and 
PDW (P=0.000) were observed in T2DM patients as com-
pared to the control group for platelet indices (Table 2).
correlations of hematological indices 
with FBg, duration of DM, and 
anthropometric measurements of study 
participants
The correlation of BMI with neutrophil count, RBC count, 
Hgb, and RDW values achieved significant but weak posi-
tive correlation in T2DM groups. Likewise, WHR achieved 
significant but weak positive correlation with RBC count, 
Hct, and Hgb in T2DM groups. Except for WHR and neu-
trophils that showed weak positive correlation (r=0.175; 
P=0.033), there was no statistically significant correlation 
between hematological profile and WHR in the control 
groups (Table 3).
Regarding the correlation of hematological indices with 
systolic and diastolic BP, only MCHC was found to be 
positively correlated with systolic BP (P=0.005) and only 
WBC count was negatively correlated with diastolic BP in 
the control group (P=0.006). However, in T2DM groups, 
MCV (P=0.036), platelet count (P=0.000), lymphocyte count 
Table 2 comparison of hematological indices of the study 
participants at gondar University hospital, northwest ethiopia, 
2015 (n=296)
Variables Mean ± SD 
(T2DM)
Mean ± SD 
(Controls)
P-value
White blood cell indices
WBcs (103 /µl) 6.59±1.42 5.56±1.38 0.000
lymphocytes (103/µl) 2.60±0.70 2.04±0.63 0.000
neutrophils (103/µl)) 3.57±1.46 3.11±1.04 0.012
MiD (103/ul) 0.80±0.53 0.71±0.43 0.120
Red blood cell indices
rBcs (106/µl) 5.12±0.57 5.1±0.54 0.755
hgb (g/dl) 15.2±1.7 15.1±1.5 0.739
hct (%) 46.7±5.1 46.4±4.2 0.609
McV (fl) 91.7±5.0 90.7±4.3 0.056
Mch (pg) 29.7±2.6 30.0±5.3 0.086
Mchc (g/dl) 32.6±2.0 32.5±1.0 0.772
rDW (fl) 47.3±2.6 45.2±3.0 0.000
Platelet indices
Platelet (103/µl) 255.7±82.0 246.3±67.4 0.280
MPV (fl) 10.4±1.1 9.9±1.1 0.001
PDW (fl) 14.5±2.1 13.4±2.1 0.000
Note: P-value ,0.05 is considered statistically significant.
Abbreviations: T2DM, type 2 diabetes mellitus; WBc, white blood cell; MiD, 
monocyte, basophil, and eosinophil; rBc, red blood cell; hgb, hemoglobin; hct, 
hematocrit; McV, mean cell volume; Mch, mean cell hemoglobin; Mchc, mean 
cell hemoglobin concentration; rDW, red blood cell distribution width; MPV, mean 
platelet volume; PDW, platelet distribution width; SD, standard deviation.
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(P=0.002), and MPV count (P=0.046) achieved statistically 
significant correlation with systolic BP, while WBC count 
(P=0.013) and platelet count (P=0.000) showed significant 
negative correlation with diastolic BP (Table 4).
In the T2DM groups, FBG showed a significant positive 
correlation with total WBC count (P=0.007), absolute lympho-
cyte count (P=0.034), absolute neutrophil count (P=0.033), and 
MPV (P=0.042). However, no statistically significant correla-
Table 3 Pearson’s correlations(r) of hematological indices with BMi and Whr among T2DM patients and healthy controls at gondar 
University hospital, northwest ethiopia, 2015 (n=296)
Variables T2DM group Control group
BMI 
r(P)
WHR 
r(P)
BMI 
r(P)
WHR 
r(P)
WBc 0.089 (0.282) 0.088 (0.285) 0.070 (0.400) 0.161 (0.051)
lymphocytes 0.031 (0.705) 0.114 (0.168) 0.189* (0.021) 0.145 (0.078)
neutrophils 0.163* (0.048) 0.088 (0.287) 0.045 (0.591) 0.175* (0.033)
MiD –0.135 (0.101) 0.044 (0.598) –0.095 (0.253) –0.073 (0.381)
rBc 0.188* (0.022) 0.196* (0.017) –0.132 (0.108) –0.066 (0.427)
hct 0.112 (0.174) 0.190* (0.021) 0.163* (0.048) –0.048 (0.565)
hgb 0.167* (0.042) 0.167* (0.042) –0.156 (0.058) –0.020 (0.807)
McV –0.091 (0.269) –0.061 (0.461) 0.006 (0.945) 0.071 (0.389)
Mch –0.167* (0.043) –0.023 (0.779) –0.084 (0.312) –0.013 (0.871)
Mchc –0.099 (0.230) 0.200* (0.015) –0.028 (0.738) –0.044 (0.596)
rDW 0.177* (0.032) 0.089 (0.281) 0.009 (0.918) 0.072 (0.385)
Platelets –0.037 (0.659) 0.052 (0.528) 0.090 (0.277) 0.018 (0.830)
PDW –0.123 (0.136) –0.024 (0.771) –0.032 (0.701) –0.039 (0.641)
MPV –0.101 (0.224) 0.070 (0.397) –0.034 (0.680) 0.128 (0.120)
Notes: *Correlation is significant at 0.05 level (two-tailed), P-value ,0.05 is considered statistically significant; r is the correlation coefficient and P is the P-value.
Abbreviations: T2DM, type 2 diabetes mellitus; Whr, Waist to hip ratio; BMi, body mass index; WBc, white blood cell; MiD, monocyte, basophil, and eosinophil; rBc, 
red blood cell; hgb, hemoglobin; hct, hematocrit; McV, mean cell volume; Mch, mean cell hemoglobin; Mchc, mean cell hemoglobin concentration; rDW, red blood cell 
distribution width; MPV: mean platelet volume; PDW, platelet distribution width.
tion was observed between hematological indices and FBG 
in the control group. Moreover, duration of illness in T2DM 
patients achieved significant positive correlation with MPV 
(P=0.004) and platelet count (P=0.011) (Table 5).
Discussion
Research evidences suggest that hematological indices 
are altered in patients with T2DM.28 In patients with DM, 
Table 4 Spearman’s correlations (rho) of hematological indices with systolic and diastolic BP among T2DM patients and healthy 
controls at gondar University hospital, northwest ethiopia, 2015 (n=296)
Variables T2DM group Control group
SBP 
rho(P)
DBP 
rho(P)
SBP 
rho(P)
DBP 
rho(P)
WBc 0.110 (0.183) –0.205* (0.013) 0.089 (0.284) –0.277* (0.006)
lymphocytes 0.062* (0.002) –0.154 (0.061) 0.065 (0.435) 0.047 (0.570)
neutrophils 0.094 (0.256) –0.110 (0.182) 0.070 (0.398) –0.259 (0.551)
MiD 0.008 (0.920) 0.089 (0.282) 0.020 (0.807) –0.109 (0.187)
rBc 0.190* (0.021) 0.122 (0.139) 0.046 (0.576) 0.095 (0.253)
hct 0.116** (0.003) 0.150 (0.068) 0.239 (0.161) 0.107 (0.196)
hgb 0.294** (0.000) 0.094 (0.254) 0.090 (0.274) 0.141 (0.088)
McV 0.172* (0.036) 0.055 (0.504) 0.007 (0.937) 0.002 (0.982)
Mch 0.059 (0.473) –0.045 (0.586) 0.106 (0.198) 0.067 (0.422)
Mchc –0.059 (0.476) –0.130 (0.116) 0.230* (0.005) 0.149 (0.071)
rDW 0.069 (0.407) 0.088 (0.287) 0.154 (0.062) 0.084 (0.311)
Platelets 0.640** (0.000) –0.321** (0.000) 0.095 (0.250) –0.148 (0.073)
PDW –0.133 (0.107) 0.069 (0.406) –0.092 (0.265) 0.027 (0.744)
MPV 0.579* (0.046) 0.040 (0.633) 0.066 (0.426) 0.073 (0.376)
Notes: **Correlation is significant at 0.01 level; *correlation is significant at 0.05 level (two-tailed); P-value ,0.05 is considered statistically significant;rho isthe correlation 
coefficient.
Abbreviations: BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; T2DM, type 2 diabetes mellitus; WBc, white blood cell; MiD, monocyte, 
basophil, and eosinophil; rBc, red blood cell; hgb, hemoglobin; hct, hematocrit; McV, mean cell volume; Mch, mean cell hemoglobin; Mchc, mean cell hemoglobin 
concentration; rDW, red blood cell distribution width; MPV, mean platelet volume; PDW, platelet distribution width.
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persistent hyperglycemia exposes RBCs to elevated glucose 
concentrations, thus resulting in glycation of hemoglobin, 
prothrombin, fibrinogen, and other proteins involved in clot-
ting mechanisms.29 In this study, RBC indices had shown 
increment in diabetic patients as compared to control group, 
although the difference was not statistically significant. This 
finding is in agreement with that reported by several previous 
studies.22,30,31 This might be the indirect features of IR syn-
drome, since it is associated with increased WBC and RBC 
counts, and increased levels of Hgb and Hct.20 Significant 
elevations of Hct and MCV might be due to the variety of 
morphological changes exhibited by RBCs and compositional 
changes in plasma associated with T2DM.32
In contrast to this study, a study conducted on Chinese 
patients with T2DM reported that a decreased RBC count 
is associated with microvascular complications.33 Likewise, 
a study performed in Tobago (Caribbean) reported that RBC 
count, Hgb concentration, and Hct levels in T2DM patients 
are lower than in the control group.34 The possible hypoth-
esis for this difference might be that chronic hyperglycemia 
causes nonenzymatic glycosylation of RBC membrane pro-
teins leading to accelerated aging of RBCs.35 Similar study 
on middle-aged and elderly Chinese population in Taiwan 
also contradicts our finding as it is reported a reduced RBC 
count in patients with IR. But similar to the results obtained 
in our study, there was no statistically significant difference 
in Hgb levels between T2DM patients and control group.22 
Another study observed that diabetics are prone to anemia 
due to reduced kidney functions and decreased production of 
erythropoietin hormone, which ultimately leads to decreased 
RBC count in the body.35
Among the RBC indices, only RDW values achieved 
statistically significant difference between T2DM and con-
trol groups. This finding is in accordance with the previous 
findings.22,36–39 This is due to the fact that high RDW indicates 
impairment of erythropoiesis, reflecting chronic inflamma-
tion and increased levels of oxidative stress, both of which 
are significant signs of T2DM that result in the RBC size 
variation.40 In contrary, studies in Turkey and Nigeria reported 
that significant difference was not observed between cases and 
controls in RDW level.39,40 Differences in study design and 
ethnic and cultural differences across the study populations 
may account for the variability of RDW across studies.
In the present study, WBC indices increased significantly 
in the T2DM group compared with the control group. The 
reason for this variation might be due to the fact that the 
high WBC count in the T2DM group is in keeping with 
the increased oxidative stress triggered by the high levels of 
hyperglycemia. Thus, polymorphonuclear and mononuclear 
WBCs can be activated by AGEs and cytokines in a state of 
hyperglycemia.41 One study has also indicated that WBC 
count is elevated in the T2DM patients and may contribute to 
the vascular complications.41 Evidence from epidemiological 
studies suggested an association between WBC count, devel-
opment of vascular complications, and diabetes risk,22,25,42 
and the authors reported that total and differential WBC 
Table 5 Pearson’s correlations(r) of hematological indices with FBg level and duration of illness among T2DM patients and healthy 
controls at gondar University hospital, northwest ethiopia, 2015 (n=296)
Variables T2DM group Control group
FBG 
r(P)
FBG 
r(P)
Duration of T2DM 
r(P)
Total WBc count 0.221** (0.007) –0.004 (0.962) 0.008 (0.923)
absolute lymphocytes 0.174* (0.034) –0.023 (0.777) 0.119 (0.149)
absolute neutrophils 0.175* (0.033) 0.003 (0.970) –0.033 (0.692)
MiD 0.083 (0.316) –0.156 (0.058) –0.014 (0.865)
rBc 0.129 (0.118) 0.081 (0.325) 0.047 (0.570)
hct 0.106 (0.201) 0.013 (0.873) 0.010 (0.905)
hgb 0.149 (0.070) 0.048 (0.566) 0.026 (0.758)
McV 0.036 (0.663) –0.073 (0.379) –0.081 (0.328)
Mch 0.083 (0.315) –0.057 (0.488) –0.045 (0.587)
Mchc 0.159 (0.053) 0.038 (0.642) –0.021 (0.798)
rDW –0.120 (0.148) –0.072 (0.384) –0.094 (0.254)
Platelets –0.048 (0.559) 0.234** (0.004) 0.029 (0.729)
PDW 0.038 (0.643) –0.006 (0.945) 0.008 (0.927)
MPV 0.614* (0.042) 0.207* (0.011) 0.007 (0.936)
Notes: **Correlation is significant at 0.01 level; *correlation is significant at 0.05 level (two-tailed); r is the correlation coefficient.
Abbreviations: FBg, fasting blood glucose; T2DM, type 2 diabetes mellitus; WBc, white blood cell; MiD, monocyte, basophil, and eosinophil; rBc, red blood cell; hgb, 
hemoglobin; hct, hematocrit; McV, mean cell volume; Mch, mean cell hemoglobin; Mchc, mean cell hemoglobin concentration; rDW, red blood cell distribution width; 
MPV, mean platelet volume; PDW, platelet distribution width.
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counts are higher in T2DM compared to apparently healthy 
individuals in congruence to our study.
In one study, the absolute MID count showed an increase 
but no significant difference was found to exist between the 
two groups. This is in agreement with the previously published 
reports of the Atherosclerosis Risk in Communities study.43 
Biological evidence suggests that inflammation might induce 
T2DM and epidemiological studies have also shown an associa-
tion between higher WBC and T2DM.22,25 However, the associa-
tion has not been systematically investigated in this study. Several 
other previous studies, consistent to our study, reported that an 
increase in WBC count, even within the normal range, was 
found to be associated with the development of complications 
in T2DM patients.44–46 The authors also reported that peripheral 
total WBC, monocyte, and neutrophil counts increased in paral-
lel with the progression of complications.44–46
This study also included the comparison of the platelet 
indices between the control and the diabetic patients. We 
observed no significant difference in platelet count between 
diabetic and control groups. However, statistically significant 
increment in MPV and PDW were found in T2DM patients, 
which is in accordance with several studies that have shown 
an increased number of large circulating platelets com-
pared with controls.39,47–51 The reason might be related to 
the vascular complications in DM patients. There might be 
small vascular bleeds due the rupture of athrothrombotic 
plagues leading to bone marrow stimulation to recruit larger 
hyperactive platelets.30,52 Moreover, osmotic swelling of 
platelets, as a result of hyperglycemia and the platelet granule 
secretions, may contribute to platelet size variation and MPV 
elevation in T2DM patients.30 The other factors might be due 
to differences in platelet function between diabetic and con-
trol individuals.18 Among the diabetic individuals, increased 
platelet aggregability and adhesiveness may be due to dif-
ferent reasons including reduced membrane fluidity, altered 
calcium and magnesium ion homeostasis, increased arachi-
donic acid metabolism leading to enhanced thromboxane 
A
2
 (TXA
2
) production, decreased nitric oxide production, 
decreased antioxidant levels, and increased expression of 
activation-dependent adhesion molecules in DM patients.53,54 
Moreover, studies have reported that increment of immature 
platelet levels, platelet aggregation, and platelet activation 
are common in T2DM patients with coronary artery diseases, 
even on those who are on aspirin treatment aimed to protect 
vascular damage.18,19 Besides, poor metabolic control, IR, 
low-grade inflammation, and hyperglycemia in T2DM 
patients have been suggested as factors influencing platelet 
function in addition to high platelet turnover.55
In this study, correlation of hematological indices with 
FBG, BP, duration of T2DM since diagnosis, BMI, and 
WHR was determined. The variables above the threshold 
cutoff values were found to be the forecasters of CVD in 
numerous populations. In our study, RBC, Hgb, MCH, and 
RDW achieved significant correlation with BMI and WHR. 
This is in harmony with a previous study conducted in 
Toronto and London, Ontario, Canada.56 A similar study in 
Brazil demonstrated an association between the hematologi-
cal indices and body adiposity.57 A study on middle-aged and 
elderly Chinese people with T2DM found that WBC count 
was positively correlated with WHR and BMI.58 In contrast 
to our study, a study in North-East Italy cohort reported that 
no associations were found between hematological indices 
and BMI in lean, overweight, or obese subgroups.59 The 
discrepancy might be due to the differences in study design 
and study population.
With respect to the correlation of hematological 
indices with systolic and diastolic BP in T2DM groups, 
MCV, platelet count, lymphocyte count, and MPV achieved 
statistically signif icant correlation with systolic BP. 
Besides, WBC and platelet counts showed significant 
negative correlation with diastolic BP. The relationship 
between level of BP and hematological indices may be 
due to the development of diabetes-related hypertension 
and dyslipidemia.60,61 Researchers reported an increased 
prevalence of hypertension in diabetics than in the non-
diabetic individuals. They hypothesized that chronic 
hyperglycemia produces a direct, toxic effect on vascular 
endothelial cells, and this condition can lead to increased 
vasoconstriction and vascular remodeling ultimately 
affecting the blood cells.62
In the present study, we found significant correlation 
of MCV and WBC with levels of systolic and diastolic BP 
in T2DM patients. In the control group, RBC, Hct, Hgb, 
and MCHC values achieved significant correlation. Other 
recent cross-sectional survey on 32,004 patients showed 
that coexistence of high BP and abnormal glucose metabo-
lism is common.63 In our study, FBG level had statistically 
significant correlation with WBC, lymphocyte, and neutro-
phil counts in T2DM patients. Congruent to ours, a study in 
Pakistan indicated that granulocyte count was positively cor-
related with FBG.47 Evidence suggests that disease chronicity 
and hyperglycemia have effects on sensorimotor control in 
DM patients.64 Duration of DM since diagnosis achieved 
significant correlation with platelet count. Clinically elevated 
platelet counts are frequently observed in diabetics with a 
long duration of disease.
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Conclusion and recommendation
FBG, MPV, PDW, absolute lymphocyte count, absolute neutro-
phil count, total white cell count, RDW, BMI, and WHR are sig-
nificantly higher among diabetic subjects compared to apparently 
healthy controls. This is a reflection of poor glycemic control 
and lifestyle changes. FBG is significantly correlated with total 
WBC, absolute lymphocyte and neutrophil counts, and MPV. The 
routine hematological profile checking of patients with T2DM 
may help to prevent complications associated with aberrations 
in hematological values. The limitation of this study is it does 
not evaluate a cause–effect relationship between variables and 
diabetes because of cross-sectional nature of the study design.
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